| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Xenon Pharmaceuticals Inc.$68.92
-2.04 (-2.87%)
B 60Pipeline Score Overvalued Pharma · Commercial
Market Cap
5.24 B
EPS
-4.70
P/E Ratio
-
Value Trade
91.16 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
88.51 M
Operating CF
-88.90 M
Total Assets
1.39 B
Total Liabilities
48.99 M
Equity
1.34 B
D/E Ratio
12,345
-2.64 %
Week
-4.51 %
1 Month
25.98 %
3 Month
35.02 %
6 Month
198.62 %
5 Year
440.62 %
All Time
Cash Data
Cash Position
1.09 B
Monthly Burn
29.63 M
Runway
34.7 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.54 M
52 Week Range
28.19 - 63.95
% held by Insiders
6.09 %
% held by Institutions
98.44 %
Enterprise Value
4.15 B
Total Shares
77.27 M
Short %
9.11 %
Float Shares
68.69 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Xenon Pharmaceuticals Inc.
724Total events
0Upcoming
96Tier-1 (high impact)
2014 – 2026Coverage
Event history 724
Q3 2026
◆NDA SubmissionAzetukalnerRegulatory Filing
NDA submission to FDA planned for Q3 2026
focal onset seizuressource ↗
May 20, 2026
◆Oral PresentationPresentation
Beyond the Right Heart Cath: 129Xe MRI for Noninvasive, Multidimensional Monitoring in PH
Pulmonary Hypertensionsource ↗
May 20, 2026
◆Poster PresentationPresentation
Periostin and Airway Fibroblasts in Obesity-associated Asthma
Asthmasource ↗
May 19, 2026
◆Oral PresentationPresentation
Establishing Standardized Mapping of 129Xe Frequency Shift Heterogeneity in Capillary Red Blood Cells
Pulmonary Vascular Diseasesource ↗
May 19, 2026
◆Poster PresentationPresentation
Illuminating Pulmonary Function on CT With Integrated 129Xe MRI Gas Exchange Maps
Methods / Validationsource ↗
May 18, 2026
◆Oral PresentationPresentation
A First-in-human Study of Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis
Rare Lung Disease / PAPsource ↗
May 18, 2026
◆Poster PresentationPresentation
Oxidant Stress and Ventilation Impairment in Obesity-related Asthma
Asthmasource ↗
May 17, 2026
◆Oral PresentationPresentation
Characterization of Lung Microstructural Injury in Bronchopulmonary Dysplasia Using 129Xe MRI
Pediatric / BPDsource ↗
May 17, 2026
◆Poster PresentationPresentation
Functional Xenon Imaging in Pulmonary Sarcoidosis – Multi-center Cohort
ILD / Sarcoidosissource ↗
May 14, 2026
Drug Pipeline Intelligence
B60
Pipeline Score $2.5B
Pipeline ValueOvervalued
Valuation Signal8
Drugs Scored0.5x
rNPV / MCap Top 86%
Small Cap (rank 129 of 912)
Percentile RankXenon Pharmaceuticals Inc. holds a solid B-grade pipeline (60/100), with $3.9B risk-adjusted pipeline value, led by Azetukalner in Major Depressive Disorder (Phase 3), across $97B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azetukalner Small molecule | Bipolar Disorder | Phase 3 | NCT07172516 | 49% | $1.3B | RECRUITING | 400 | VERY_FAST | B (67) | Aug 1, 2028 | LOW_RISK | LOW Jun 4, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
azetukalner | focal onset seizures | Phase 3 | 2026-04-20 | nearly 40% of patients achieving 12 months of seizure freedom; median of 13 seizures per month at baseline; nearly 40% of patients treated for at least 48 months achieved at least 12 months of seizure freedom Read More | Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting Read More | |
azetukalner | focal onset seizures | Phase 3 | 2026-04-20 | nearly 40% of patients achieving 12 months of seizure freedom; median of 13 seizures per month at baseline; nearly 40% of patients treated for at least 48 months achieved at least 12 months of seizure freedom Read More | Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting Read More | |
azetukalner | focal onset seizures | Phase 3 | 2026-04-20 | nearly 40% of patients achieving 12 months of seizure freedom; median of 13 seizures per month at baseline; nearly 40% of patients treated for at least 48 months achieved at least 12 months of seizure freedom Read More | Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XENE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XENE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 29, 2026
Xenon Pharmaceuticals has announced equity inducement grants to 10 new non-officer employees, totaling 32,750 share options and 19,200 restricted share units. These grants were approved by the Compensation Committee and are part of the company's strategy to attract talent. The share options have an exercise price of $54.79 and will vest over four years.
Read more →XENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced the granting of equity inducement awards to 10 new non-officer employees as part of their recruitment strategy under Nasdaq Listing Rule 5635(c)(4). The inducements include a total of 32,750 share options and 19,200 restricted share units (RSUs), aimed at enhancing employee retention and performance alignment. The share options have an exercise price of $54.79, aligning with the market price, while vesting periods are structured to encourage long-term commitment.
Read more →XENEXenon Reports Q1 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals reported positive Q1 2026 financial results, highlighting successful outcomes from the X-TOLE2 study of azetukalner for focal onset seizures. The company is preparing to submit a New Drug Application (NDA) to the FDA in the third quarter of 2026. Additionally, Xenon is advancing multiple Phase 3 studies in epilepsy and neuropsychiatry, with a strong cash position supporting its initiatives.
Read more →XENEXenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026
Polarean will showcase its Xenon MRI technology at the ATS 2026 Respiratory Innovation Summit and International Conference, highlighting its role as a cardiopulmonary biomarker platform in drug development. Chief Business Officer Alex Dusek will present on utilizing Xenon MRI to enhance clinical trial designs. The company aims to address critical needs in pulmonary medicine and has garnered recognition through more than 20 presentations reflecting ongoing research and clinical applications. The advancements are particularly focused on pediatric populations and treatment response assessments.
Read more →XENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Xenon Pharmaceuticals announced equity inducement grants to seven new non-officer employees, totaling 25,600 share options and 15,000 restricted share units. These grants were approved by the Compensation Committee and are part of the company's strategy to attract talent. The options have a 10-year term and vest over four years, while the RSUs vest over four anniversaries.
Read more →XENEXenon to Report Q1 2026 Financial Results on May 7, 2026
Xenon Pharmaceuticals Inc. has announced that it will report its first quarter 2026 financial results on May 7, 2026. The company will provide a business update after U.S. financial markets close, along with a live webcast for interested parties. This presentation reflects the company's ongoing commitment to keeping stakeholders informed about its financial health and developments.
Read more →XENEXenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Xenon Pharmaceuticals presented positive results from the Phase 3 X-TOLE2 study at the AAN Annual Meeting, demonstrating the efficacy and safety of azetukalner for focal onset seizures. The data revealed significant improvements in seizure control, with nearly 40% of patients achieving 12 months of seizure freedom. The company plans to submit a New Drug Application to the FDA in Q3 2026.
Read more →XENEXenon to Present at Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. has announced its participation in four investor conferences scheduled for the second quarter of 2026. These events include notable conferences such as the Bloom Burton & Co. Healthcare Investor Conference and the Bank of America Global Healthcare Conference. The company seeks to enhance its visibility and investor engagement through these presentations, providing updates on its drug development initiatives. Details regarding the presentations and webcasts can be found on Xenon’s website.
Read more →XENEXenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Xenon Pharmaceuticals will present five abstracts at the 2026 AAN Annual Meeting, including late-breaking results from the Phase 3 X-TOLE2 study of azetukalner for focal onset seizures. The presentations will also cover long-term safety data and real-world insights into epilepsy treatment challenges. The meeting is scheduled for April 18-22, 2026, in Chicago.
Read more →XENEXenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Xenon Pharmaceuticals has successfully closed a public offering, raising approximately $747.5 million. The offering included 12,236,843 common shares, with a portion sold under the underwriters' option. This funding will support the company's drug development efforts, particularly for its lead molecule in Phase 3 trials for epilepsy and depression disorders.
Read more →XENEXenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
Xenon Pharmaceuticals has announced the pricing of its upsized public offering, which includes 10,526,317 common shares priced at $57.00 each and pre-funded warrants for $56.9999. The offering is projected to generate approximately $650 million in gross proceeds, pending the closing scheduled for March 12, 2026. This fundraising will likely bolster the company's endeavors in drug discovery and clinical development within the neuroscience sector.
Read more →XENE▲ +49.6%on this newsshared move
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner, showing a significant reduction in focal onset seizures. The study met its primary endpoint, demonstrating a median percent change of -53.2% in seizure frequency for the 25 mg dose compared to placebo. Azetukalner exhibited a favorable safety profile and is set for a New Drug Application submission to the FDA in Q3 2026.
Read more →XENE▲ +49.6%on this newsshared move
Xenon Pharmaceuticals Announces Proposed Public Offering
Xenon Pharmaceuticals has announced a proposed public offering of $500 million in common shares. This offering, initiated as part of its existing shelf registration statement, seeks to strengthen the company's financial resources for drug development. Major financial institutions will manage the offering, but it remains contingent on market conditions and other factors that could influence its completion. The announcement comes amid ongoing discussions regarding Xenon's pipeline, particularly its lead molecule in clinical trials.
Read more →XENE▲ +49.6%on this newsshared move
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
Xenon Pharmaceuticals Inc. will announce topline results from its Phase 3 X-TOLE2 study of azetukalner, a KV7 potassium channel opener, for treating focal onset seizures. The announcement is scheduled for March 9, 2026, with a conference call and webcast to provide further details. This study represents a significant step in the clinical development of a potential therapeutic alternative for patients affected by seizures.
Read more →XENEXenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
Xenon Pharmaceuticals reported its Q4 and full-year 2025 financial results, highlighting strong progress in Phase 3 trials for azetukalner, a KV7 potassium channel opener. The company anticipates topline data from the X-TOLE2 study in March 2026, followed by a potential NDA submission later in the year. The pipeline also includes early-stage ion channel modulators for pain management.
Read more →XENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
Xenon Pharmaceuticals announced the granting of equity inducement options to ten new employees, totaling 42,300 share options. These options were approved by the Compensation Committee and have an exercise price of $40.74, equal to the closing price on the grant date. The options will vest over four years, reflecting the company's commitment to its new hires.
Read more →XENEXenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals outlined its progress and upcoming milestones at the 2026 J.P. Morgan Healthcare Conference. The company is set to report topline data for its X-TOLE2 Phase 3 study of azetukalner, aimed at treating focal onset seizures. This study represents a critical step towards regulatory submission and potential market launch. Additionally, Xenon is advancing multiple other Phase 3 studies in epilepsy and neuropsychiatry.
Read more →XENE▼ -6.1%on this news
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12-15, 2026, in San Francisco. The company will provide a live audio webcast of its presentation, which will be available for replay. Xenon is focused on developing therapeutics for epilepsy, major depressive disorder, and bipolar depression.
Read more →XENEXenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
Xenon Pharmaceuticals presented new data at AES 2025, showcasing interim 48-month results from the X-TOLE open-label extension study of azetukalner in patients with focal onset seizures. The data revealed significant reductions in seizure frequency and highlighted the potential for prolonged seizure freedom. The company aims to share Phase 3 data from the X-TOLE2 study in early 2026.
Read more →XENEXenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
Xenon Pharmaceuticals announced an upcoming investor webinar to present data from the American Epilepsy Society Annual Meeting (AES 2025). The focus will be on long-term data from the X-TOLE study of azetukalner for focal onset seizures and real-world data on depression in epilepsy. The company is also preparing for the commercialization of azetukalner.
Read more →XENEXenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
Xenon Pharmaceuticals will present new data on azetukalner at the AES 2025 meeting, focusing on its long-term effects in patients with focal onset seizures. The company will showcase findings from the X-TOLE open-label extension study and host a symposium on depression in epilepsy. The event will take place from December 5-9, 2025, in Atlanta, Georgia.
Read more →XENEXenon Reports Third Quarter 2025 Financial Results & Business Update
Xenon Pharmaceuticals reported its third quarter 2025 financial results, highlighting the completion of patient randomization in the Phase 3 X-TOLE2 study of azetukalner, with topline data expected in early 2026. The company is also advancing its Phase 3 studies in major depressive disorder and bipolar depression, alongside ongoing Phase 1 studies. The appointment of Tucker Kelly as CFO is anticipated to support the upcoming launch of azetukalner.
Read more →XENEXenon to Report Q3 2025 Financial Results on November 3, 2025
Xenon Pharmaceuticals Inc. announced it will report its Q3 2025 financial results on November 3, 2025. The company, focused on neuroscience, is advancing its lead molecule in Phase 3 trials for epilepsy and mood disorders. A live webcast will be available for investors to follow the presentation and updates.
Read more →XENEXenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Xenon Pharmaceuticals has appointed Tucker Kelly as Chief Financial Officer, bringing over 25 years of experience in corporate finance. His role will be pivotal as the company prepares for the commercialization of its lead candidate, azetukalner, currently in Phase 3 trials for epilepsy and other conditions. Kelly's previous experience includes significant roles in various life sciences companies.
Read more →XENEXenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
Xenon Pharmaceuticals Inc. will host an investor webinar to discuss its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain. The webinar will be accessible via the company's website, with a replay available afterward. Xenon's lead molecule is currently in Phase 3 trials for epilepsy and mood disorders, while its pain programs are in Phase 1 development.
Read more →XENEXenon Reports Second Quarter 2025 Financial Results & Business Update – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner
Xenon Pharmaceuticals reported its financial results for the second quarter of 2025, highlighting the completion of patient recruitment for the Phase 3 X-TOLE2 study of azetukalner, with topline data expected in early 2026. In addition to ongoing epilepsy trials, the company has initiated Phase 3 studies for major depressive disorder and bipolar depression. Despite the progress, Xenon faced a net loss of $84.7 million for the quarter, reflecting higher research expenses and other financial challenges. The appointment of a new Chief Commercial Officer aims to enhance the company's commercial strategy as it moves toward potential product launches.
Read more →XENE▲ +8.7%on this news
Xenon to Report Q2 2025 Financial Results on August 11, 2025
Xenon Pharmaceuticals Inc. has announced that it will report its financial results for Q2 2025 on August 11, 2025, after U.S. markets close. The announcement also includes plans for a conference call and webcast for investors and analysts. The company focuses on neuroscience and is advancing treatments for severe conditions like epilepsy and depression. Azetukalner, a key product, is in late-stage clinical development and aims to address significant medical needs.
Read more →XENEXenon Joins the Russell 3000 and Russell 2000 Indexes
Xenon Pharmaceuticals Inc. has announced its addition to the Russell 3000 and Russell 2000 Indexes, effective after the close of U.S. equity markets on June 27, 2025. This inclusion signifies a significant milestone for the company, enhancing its visibility and potentially attracting greater interest from institutional investors. The Russell 2000 Index specifically tracks the performance of smaller companies within a larger cohort, and this move could lead to better benchmark recognition for Xenon.
Read more →XENEXenon Announces Appointment of Darren Cline as Chief Commercial Officer
Xenon Pharmaceuticals Inc. has appointed Darren Cline as Chief Commercial Officer to lead its commercial strategy and operations, focusing initially on the Phase 3 candidate azetukalner for epilepsy. Mr. Cline brings over 30 years of experience in the biopharmaceutical industry, having previously overseen significant product launches in epilepsy. His appointment is timely as Xenon prepares for important Phase 3 trial data expected in early 2026, potentially leading to the company’s first commercial launch.
Read more →XENEXenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Xenon Pharmaceuticals Inc. has announced its participation at the Goldman Sachs 46th Annual Global Healthcare Conference, scheduled for June 9-11, 2025, in Miami, FL. Ian Mortimer, the company's CEO, will present on June 10, 2025, at 3:20 PM Eastern Time. The presentation will be available through a live audio webcast on the company's website, which will also be accessible for replay afterward. Xenon focuses on neuroscience therapies and is advancing its product portfolio with a particular emphasis on treatments for epilepsy and depression.
Read more →XENEXenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum
Polarean Imaging plc's Xenon MRI will be prominently featured at the ATS 2025 Respiratory Innovation Summit and the International Conference. Its selection for these events reflects the increasing recognition of the technology's significance in clinical imaging and drug development. Throughout the conference, over 30 presentations will highlight the versatility of Xenon MRI across various respiratory conditions, signifying its enduring impact on pulmonary medicine. The continued support from industry leaders and researchers indicates a strong future for Xenon MRI in shaping respiratory care.
Read more →XENEXenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Xenon Pharmaceuticals Inc. will present at the 2025 RBC Capital Markets Global Healthcare Conference in New York on May 21, 2025. The presentation will be led by Ian Mortimer, CEO, and will be accessible via a live audio webcast. The company focuses on developing therapeutics for conditions like epilepsy and depression, with a key highlight being its late-stage candidate, Azetukalner.
Read more →XENEXenon Reports First Quarter 2025 Financial Results and Provides Business Update – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated
Xenon Pharmaceuticals reported its Q1 2025 financial results and provided updates on its clinical trials. Recruitment for the Phase 3 azetukalner X-TOLE2 study is expected to complete soon, with topline data anticipated in early 2026. The company is progressing on multiple initiatives, including several Phase 3 studies in major depressive disorder and bipolar depression. Despite a significant increase in net losses, Xenon continues to demonstrate positive drug activity in its trials, positioning itself for future milestones.
Read more →XENEXenon to Report Q1 2025 Financial Results on May 12, 2025
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has announced it will report its financial results for the first quarter of 2025 on May 12, 2025, after U.S. market close. The company will provide a business update during this time. A webcast will be available for those interested in the company's developments, and it will be accessible on the company's website post-event. Xenon focuses on innovative treatments for neuroscience-related conditions.
Read more →XENEXenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
Xenon Pharmaceuticals will present long-term data from its X-TOLE OLE study of azetukalner at the AAN 2025 annual meeting. This includes a 36-month analysis showcasing efficacy in reducing focal onset seizures and findings on the mental health burdens faced by patients. Three posters will cover safety and efficacy outcomes and an exploratory efficacy analysis among seizure subtypes. These results highlight the potential of azetukalner as a viable therapy for those suffering from uncontrolled seizures.
Read more →XENEXenon to Present at Stifel 2025 Virtual CNS Forum
Xenon Pharmaceuticals Inc. will present at the Stifel 2025 Virtual CNS Forum on March 19, 2025. The presentation will feature Dr. Chris Kenney, the Chief Medical Officer, and will be available via a live audio webcast. The company continues to focus on developing therapeutics for neurological conditions, emphasizing its innovative product Azetukalner, which targets high unmet medical needs.
Read more →XENEXenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update – Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercia
Xenon Pharmaceuticals has reported its fourth quarter and full year financial results for 2024, highlighting its advancing Phase 3 clinical trials for azetukalner, a treatment for epilepsy and neuropsychiatric disorders. Notably, topline data from its focal onset seizures study is anticipated in late 2025, which could facilitate an NDA filing. The company has substantial cash reserves to fund its operations through 2027, but it faces rising R&D expenses, primarily due to the azetukalner program. Additionally, the company is preparing for the departure of CFO Sherry Aulin, who will be stepping down in mid-2025.
Read more →XENEXenon to Present at the 45th Annual TD Cowen Healthcare Conference
Xenon Pharmaceuticals Inc. has announced its participation in the upcoming 45th Annual TD Cowen Healthcare Conference in Boston, scheduled for March 3-5, 2025. The presentation will take place on March 4, 2025, at 10:30 AM Eastern Time, featuring CEO Ian Mortimer and CFO Sherry Aulin. A live audio webcast will be available on the company's website, with replays to follow after the event. Xenon continues to advance its innovative therapies targeting unmet medical needs in neuroscience.
Read more →XENEXenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
Xenon Pharmaceuticals Inc. has announced that it will report its financial results for the fourth quarter of 2024 on February 27, 2025. The announcement emphasizes Xenon's dedication to neuroscience-focused therapeutics aimed at addressing significant medical needs. A live conference call and webcast will be available for stakeholders, allowing for real-time engagement. This event reflects the company's ongoing developments and commitment to transparency with investors.
Read more →XENEXenon Outlines Key Corporate Milestone Opportunities for 2025
Xenon Pharmaceuticals has outlined significant milestones for 2025, including the anticipated topline data from the first Phase 3 FOS study, which is pivotal for a potential NDA filing for azetukalner. The company has initiated its first Phase 3 study for major depressive disorder (MDD) and is planning more IND filings in the year ahead. They also reported positive long-term results from their ongoing studies, reinforcing the drug's strong efficacy and safety profile. These advancements mark a transition for Xenon towards a commercial stage within the biopharmaceutical industry.
Read more →XENEXenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals Inc. has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, taking place in San Francisco from January 13-16, 2025. The presentation will be led by Ian Mortimer, the company's President and Chief Executive Officer. A live audio webcast of the event will be available on their website. Xenon is recognized for its focus on neuroscience and its development of therapeutics for conditions such as epilepsy and depression.
Read more →XENEXenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
Xenon Pharmaceuticals presented new long-term data from its X-TOLE OLE study of azetukalner at the AES 2024 meeting. The results indicate significant sustained reductions in seizure frequency, with 85% maintained at month 36, and 32.7% of patients achieving seizure freedom for at least a year. The study also emphasizes the ongoing need for new effective epilepsy therapies due to the high burden of focal onset seizures on patients' quality of life. Additionally, pre-clinical data suggests potential protective effects of a Nav1.1 potentiator against seizures in a Dravet model.
Read more →XENEXenon to Showcase New Long-Term Azetukalner Data at AES 2024
Xenon Pharmaceuticals (Nasdaq: XENE) has announced plans to present five posters at the upcoming American Epilepsy Society Annual Meeting (AES 2024) in December. The presentations will include long-term data on azetukalner from the X-TOLE open-label extension study and explore the mental health burdens associated with focal onset seizures. Additionally, new pre-clinical data from the company's Nav1.1 program will be showcased. This event reflects the company's ongoing commitment to advancing therapeutics in the field of epilepsy.
Read more →XENEXenon Reports Q3 2024 Financial Results and Business Update – Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label e
Xenon Pharmaceuticals (XENE) recently reported its Q3 2024 financial results, highlighting the advancement of its Phase 3 epilepsy program with topline FOS data expected in the second half of 2025. The company is also preparing to initiate its Phase 3 MDD program by year-end and expanding its ion channel portfolio to support multiple IND filings in 2025. Despite a net loss of $62.8 million due to rising research expenses, Xenon remains optimistic about the long-term efficacy of its lead candidate, azetukalner, in managing various epilepsy conditions.
Read more →XENEXenon to Report Q3 2024 Financial Results on November 12, 2024
Xenon Pharmaceuticals Inc. has announced that it will report its Q3 2024 financial results after the close of U.S. financial markets on November 12, 2024. A live webcast of the company presentation will be available, and investors can pre-register for the event. The firm focuses on developing therapeutics for neurological conditions, including epilepsy and depression, emphasizing their commitment to addressing significant medical needs.
Read more →XENEXenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
Xenon Pharmaceuticals Inc. announced its participation in the BofA Securities 2024 CNS Therapeutics Virtual Conference scheduled for October 7, 2024. The company will present a fireside chat, which will be available via live webcast and for replay afterward. Xenon is focused on developing innovative therapeutics for neurological and psychiatric disorders, including epilepsy and depression, with a notable emphasis on its lead product, Azetukalner. The presentation is aimed at investors and stakeholders interested in advancements in CNS therapeutics.
Read more →XENEXenon Showcases Azetukalner Data at 15th European Epilepsy Congress
Xenon Pharmaceuticals presented long-term data for azetukalner at the 15th European Epilepsy Congress, showcasing its efficacy in reducing focal onset seizures significantly. The data revealed a greater than 90% reduction in median monthly seizure frequency in patients after 30 months of treatment. Moreover, approximately 25% of patients experienced a period of seizure freedom lasting a year or longer. These findings emphasize the potential of azetukalner to improve quality of life in epilepsy patients, addressing a critical area in therapeutic need.
Read more →XENEXenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Xenon Pharmaceuticals has announced the appointment of Matthew D. Ronsheim, Ph.D., as Chief Operating Officer. In his role, he will manage Chemistry, Manufacturing and Controls as well as oversee the pipeline for their lead product, azetukalner, aimed at treating epilepsy and major depressive disorder. Dr. Ronsheim brings 25 years of experience in pharmaceutical development and commercialization, and his leadership is expected to support Xenon's growth as it progresses through Phase 3 clinical programs. The company remains committed to addressing significant gaps in therapies for neurological conditions.
Read more →XENEXenon Reports Q2 2024 Financial Results and Business Update – Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025 – MDD program on track with Phase 3 study expected to
Xenon Pharmaceuticals reported its Q2 2024 financial results along with updates on its clinical development programs. The company is progressing with its Phase 3 epilepsy program, with topline data from X-TOLE2 expected in the second half of 2025. Additionally, Xenon plans to initiate a Phase 3 study for major depressive disorder in H2 2024. The company's strong cash position allows it to fund operations into 2027, despite increased research and development expenses and a higher net loss this quarter.
Read more →XENEXenon to Report Q2 2024 Financial Results on August 8, 2024
Xenon Pharmaceuticals Inc. has announced that it will report its financial and operating results for the second quarter of 2024 after the close of U.S. financial markets on August 8, 2024. Following the announcement, the company will host a conference call and webcast to discuss these results. Xenon, which focuses on neuroscience, is developing innovative therapeutics aimed at addressing significant medical needs in neurological and psychiatric disorders, with their lead product in late-stage clinical development for multiple indications.
Read more →XENEXenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Xenon Pharmaceuticals Inc. announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 10-13, 2024, in Miami, FL. The company's presentation will take place on June 12, 2024, at 4:00 pm Eastern Time and will feature CEO Ian Mortimer and CCO Chris Von Seggern. A live webcast of the presentation will be available on the company's website, with an option for replay afterward. This event highlights Xenon's commitment to advancing treatments for neurological and psychiatric disorders.
Read more →XENEXenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
Xenon Pharmaceuticals presented data from its Phase 2 X-NOVA clinical trial for azetukalner (XEN1101) in major depressive disorder (MDD) at the ASCP 2024 Annual Meeting. The results showed a clinically meaningful reduction in depression symptoms with early onset of action for azetukalner. The company indicated a potential differentiating safety profile compared to existing antidepressants. Moving forward, Xenon plans to initiate a Phase 3 clinical program in the second half of the year to further explore the drug's efficacy.
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in
Xenon Pharmaceuticals reported its first quarter 2024 financial results, highlighting progress in its Phase 3 epilepsy program and a successful FDA interaction for its MDD program. The nonproprietary name azetukalner for XEN1101 has been approved, marking a key advancement toward commercialization. Despite optimistic milestones, the company reported an increased net loss and rising research and development expenses, which could influence its financial outlook. The completion of patient enrollment for the epilepsy program is anticipated in late 2024 to early 2025.
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals reported its financial results for Q1 2024, highlighting progress in its clinical programs, particularly for azetukalner (XEN1101) in treating epilepsy and major depressive disorder (MDD). Approval for 'azetukalner' as the generic name is viewed as a significant milestone. The company anticipates initiating Phase 3 trials for MDD later this year, leveraging positive findings from a proof-of-concept study. Despite holding $885.4 million in cash, Xenon experienced a net loss increase, primarily due to higher research and development expenses.
Read more →XENEXenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
Xenon Pharmaceuticals Inc. has announced its participation in the BofA Securities Health Care Conference 2024, set to take place from May 14 to 16 in Las Vegas, NV. The company's presentation is scheduled for May 15, 2024, at 3:40 PM PT and will feature CEO Ian Mortimer and CFO Sherry Aulin. Attendees can access a live webcast of the event through Xenon's website, with a replay option available afterwards.
Read more →XENEXenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Xenon Pharmaceuticals Inc. announced its participation in the 2024 RBC Capital Markets Global Healthcare Conference scheduled for May 14-15, 2024, in New York. Company executives, including CEO Ian Mortimer and CFO Sherry Aulin, will present during the event. A live webcast of the presentation will be available on the company's website, offering broader accessibility to interested stakeholders. This engagement underscores Xenon's commitment to advancing neuroscience-focused therapeutics.
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals Inc. announced it will report its first quarter 2024 financial and operating results on May 9, 2024. A conference call and webcast will follow the report, enabling investor participation and inquiries. The company is focused on developing innovative therapeutics for neurological and psychiatric disorders, including epilepsy and depression. Interested parties are encouraged to pre-register for the event to gain access to unique identifiers for the call.
Read more →XENEXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
Xenon Pharmaceuticals Inc. announced the presentation of clinical data for XEN1101 at the American Academy of Neurology 2024 Annual Meeting. The presentations include interim data from the ongoing X-TOLE study and insights on disease severity affecting patient responder rates. This event allows Xenon to engage with leading neurologists to discuss their late-stage research in epilepsy and major depressive disorder. They will also host an exhibit booth to further showcase their work.
Read more →XENEXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Xenon Pharmaceuticals Inc. has announced its participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16-17, 2024. The presentation will feature Ian Mortimer, the company's President and CEO, and will include a live webcast available on the company's website. This event highlights Xenon's commitment to advancing therapeutics for neurological and psychiatric disorders.
Read more →XENEXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Xenon Pharmaceuticals Inc. has announced its participation in the 23rd Annual Needham Virtual Healthcare Conference scheduled for April 8-11, 2024. Ian Mortimer, the company's President and CEO, along with CFO Sherry Aulin, will present on April 11, 2024. A live webcast of the presentation will be accessible on the company’s website, providing an opportunity for investors and stakeholders to hear directly from the company’s leadership. Xenon focuses on addressing high unmet medical needs in neurology and psychiatry.
Read more →XENEXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
Xenon Pharmaceuticals Inc. has announced its participation in the Stifel 2024 Virtual CNS Days event, scheduled for March 19, 2024. During this event, key executives, including the Chief Financial Officer and Chief Commercial Officer, will present insights on the company’s progress and pipeline. A live webcast of the presentation will be accessible on Xenon’s website, with a replay available afterward.
Read more →XENEXenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
Xenon Pharmaceuticals Inc. plans to present at the upcoming Leerink Partners Global Biopharma Conference 2024, scheduled for March 11-13 in Miami, FL. The presentation will be led by key executives including Ian Mortimer, President and CEO, and Sherry Aulin, CFO. A live webcast of the event will be available on the company's website, highlighting their innovations in neurological and psychiatric disorders. The event reflects Xenon's commitment to addressing unmet medical needs in these therapeutic areas.
Read more →XENEXenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset
Xenon Pharmaceuticals reported its financial results for Q4 and the full year of 2023, highlighting advancements in its XEN1101 Phase 3 epilepsy program involving ongoing trials, X-TOLE2 and X-TOLE3, and plans for a Phase 3 trial in major depressive disorder (MDD). The company maintains a strong financial position with around $930 million in resources expected to support its clinical programs into 2027. Noteworthy is the progress in the XEN1101 trials, with patient enrollment for X-TOLE2 expected to conclude in late 2024 to early 2025. The company aims to leverage its drug discovery capabilities for future indications.
Read more →XENEXenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals announced its financial results for Q4 and full year 2023, highlighting advancements in its XEN1101 programs for epilepsy and major depressive disorder. Notably, the company plans to hold an end-of-Phase 2 meeting with the FDA in April to support upcoming Phase 3 trials for depression in 2024. With a strong financial backing of approximately $930 million, Xenon aims to advance its clinical development while strategically considering other neurological indications. Despite a recorded net loss, the company remains optimistic about its pipeline and the enthusiasm surrounding its lead product.
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals Inc. announced that it will be reporting its fourth quarter and full year 2023 financial results on February 29, 2024. A conference call and webcast are scheduled to take place afterward at 4:30 PM Eastern Time. This event aims to provide updates not only on financial performance but also on the company’s corporate developments. In anticipation of this, the company has emphasized its commitment to developing therapies for neurological disorders.
Read more →XENE▲ +5.2%on this news
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
Xenon Pharmaceuticals has announced key milestones for 2024, emphasizing the completion of patient enrollment in its Phase 3 X-TOLE2 clinical trial for focal onset seizures and plans to initiate a Phase 3 program for major depressive disorder. The company has reported promising interim results from its XEN1101 drug across various indications. Moreover, ongoing collaborations and advancements in preclinical studies further bolster the company's position. However, challenges related to clinical outcomes and regulatory approvals persist.
Read more →XENEXenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals Inc. announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 8-11, 2024, in San Francisco, CA. Ian Mortimer, the President and Chief Executive Officer, will present on January 8 from 9-9:40 AM Pacific Time. A live audio webcast of the presentation will be available on the company's website, with a replay provided afterwards. This participation emphasizes Xenon's focus on developing innovative therapeutics for neurological disorders.
Read more →XENEXenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Xenon Pharmaceuticals Inc. has announced the successful closing of its underwritten public offering, raising approximately $345 million. The offering consisted of 9,846,157 common shares, including additional shares purchased under the underwriters' option. The shares were priced at $32.50 each, showing strong market interest. The offering's successful execution reflects the company's solid financial position and growth prospects.
Read more →XENEXenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
Xenon Pharmaceuticals provided updates on its neurology pipeline at the American Epilepsy Society meeting. CEO Ian Mortimer highlighted interim data from the Phase 2b X-TOLE trial for XEN1101, indicating high seizure freedom rates among long-term patients. The company plans to present additional findings related to patient quality of life and mental health burdens associated with epilepsy, as well as positive topline data from its major depressive disorder studies.
Read more →XENE▲ +8.4%on this newsshared move
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
Xenon Pharmaceuticals has announced the pricing of an upsized public offering of approximately $300 million, consisting of 8,461,542 common shares and pre-funded warrants. The shares are priced at $32.50 each, with potential additional shares being offered within 30 days. The offering is subject to customary closing conditions and is expected to close around December 4, 2023. Notably, uncertainties in market conditions pose potential challenges to the successful completion of the offering.
Read more →XENE▲ +17.8%on this newsshared move
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
Xenon Pharmaceuticals announced topline results from its Phase 2 X-NOVA clinical trial evaluating XEN1101 in patients with major depressive disorder. The trial showed promising efficacy with statistically significant improvements on multiple rating scales, particularly at the 20mg dosage. Additionally, XEN1101 was well tolerated with a low incidence of treatment-emergent adverse events. The company indicated potential for future development of XEN1101, highlighting its unique mechanism of action in addressing both depression and related symptoms.
Read more →XENE▲ +17.8%on this newsshared move
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD) Conference call today at 8:30 am ET VANCOUVER, British Columb
Xenon Pharmaceuticals announced topline results from the Phase 2 X-NOVA clinical trial of XEN1101 for Major Depressive Disorder (MDD). The study indicated a dose-dependent response, with statistically significant results on various depression scales, including the HAM-D17 and SHAPS at week 6. Safety data showed that XEN1101 was well tolerated, with low rates of treatment-emergent adverse events. Despite the positive outcomes, the primary endpoint did not achieve statistical significance. The company plans further development of XEN1101 for MDD and other indications.
Read more →XENE▼ -6.7%on this news
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
Xenon Pharmaceuticals has received an update from its partner Neurocrine Biosciences regarding the Phase 2 clinical trial of NBI-921352 for focal onset seizures, which has not demonstrated significant efficacy. In light of these results, Neurocrine has stated that it will not pursue further development of the drug for this indication. Xenon plans to collaborate with Neurocrine to analyze the trial data and assess its implications for another ongoing study of the drug in SCN8A-developmental epileptic encephalopathy. The company also mentioned that Neurocrine is advancing a pre-clinical dual selective Nav1.2/1.6 inhibitor as part of their collaboration.
Read more →XENE▼ -6.7%on this news
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Redu
Xenon Pharmaceuticals announced that its partnered program with Neurocrine Biosciences did not yield positive results in a Phase 2 trial for NBI-921352, targeting focal onset seizures. The trial failed to show a meaningful reduction in seizure frequency, leading Neurocrine to halt further development of the product in this indication. Despite the setback, Xenon remains committed to analyzing the trial data to inform ongoing research into NBI-921352 for other conditions, including SCN8A-developmental epileptic encephalopathy.
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals reported its third quarter financial results alongside updates on its clinical programs. The company is on schedule to release topline data for the Phase 2 X-NOVA trial in major depressive disorder by late November or mid-December. Meanwhile, the Phase 3 epilepsy program, which includes trials such as X-TOLE2 and X-ACKT, continues to progress with patient enrollment anticipated to complete in late 2024. Despite an increased net loss, Xenon has substantial cash reserves to support ongoing operations into 2026.
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder on track for late Novembe
Xenon Pharmaceuticals reported its financial results for Q3 2023, highlighting an anticipated topline readout from the Phase 2 X-NOVA clinical trial for major depressive disorder (MDD) due between late November and mid-December. The company continues to advance its XEN1101 program with ongoing Phase 3 trials for epilepsy. Despite promising developments, Xenon faced an increase in net losses amid rising expenses linked to their clinical programs, as well as a decline in cash reserves. A conference call was scheduled to discuss these financial results further.
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals Inc. has announced it will release its third quarter 2023 financial and operating results after the close of U.S. markets on November 8, 2023. The announcement includes details for a conference call and webcast where executives will discuss the results. The company is focused on developing innovative therapeutics for neurological disorders, particularly epilepsy. A live audio webcast will also be available for replay after the event.
Read more →XENEXenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
Xenon Pharmaceuticals announced the publication of Phase 2b trial results for XEN1101 in JAMA Neurology, indicating its efficacy in treating focal epilepsy. In the trial, patients experienced notable reductions in seizure frequency. XEN1101 is advancing to Phase 3 clinical trials, reflecting the company's commitment to developing new therapies for epilepsy. The firm also plans to share additional data at the upcoming American Epilepsy Society meeting in December 2023.
Read more →XENEXenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
Xenon Pharmaceuticals Inc. announced it will present at the Jefferies Inaugural Biotech CNS/Neuro Summit on October 11, 2023. The presentation will feature CEO Ian Mortimer and CFO Sherry Aulin. A live webcast of the event will be available, allowing audiences to participate and learn about Xenon's advancements in neurology-focused therapeutics. The company emphasizes its commitment to addressing unmet medical needs in neurological disorders.
Read more →XENEXenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Xenon Pharmaceuticals Inc. announced its participation in TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit scheduled for September 20, 2023. The company will be represented by Ian Mortimer, President and CEO, and Sherry Aulin, CFO, during a live webcast presentation. This event highlights Xenon's commitment to developing innovative therapies for neurological disorders, particularly in neurology and epilepsy. The webcast will be accessible via the company's website, allowing for broader audience engagement.
Read more →XENEXenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
Xenon Pharmaceuticals has announced an upcoming investor webinar that will feature discussions with leading key opinion leaders on the topic of major depressive disorder and the company's product XEN1101. Scheduled for September 19, 2023, from 11:30 am to 1 pm ET, the webinar will allow participants to submit questions in real-time. This event underscores Xenon's commitment to addressing high unmet medical needs in the field of neurology.
Read more →XENEXenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
Xenon Pharmaceuticals presented new interim data on XEN1101 at the 35th International Epilepsy Congress which demonstrates improvements in overall quality-of-life metrics for epilepsy patients. The data was derived from the Phase 2b X-TOLE open-label extension study and indicated sustained seizure reduction and enhancements in various quality-of-life subscales. No new safety signals were reported, supporting the drug's favorable safety profile in ongoing Phase 3 trials for focal onset and primary generalized tonic-clonic seizures. The presentations aimed to connect with experts in the epilepsy field while showcasing promising clinical results.
Read more →XENEXenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
Xenon Pharmaceuticals Inc. has announced its participation in the Wells Fargo 2023 Healthcare Conference scheduled for September 6-8, 2023. Ian Mortimer, the President and CEO, along with Chief Commercial Officer Chris Von Seggern, will present during a fireside chat. This event aims to showcase Xenon's innovative therapeutic developments for neurological disorders, particularly focusing on epilepsy. A live webcast of the presentation will be available on their website.
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals has announced the completion of patient enrollment in its Phase 2 X-NOVA clinical trial for major depressive disorder, with topline data expected by late November to mid-December. The company is also making progress in its Phase 3 epilepsy trials, specifically targeting focal onset seizures and primary generalized tonic-clonic seizures. Financially, Xenon reported a net loss of $47.5 million for the second quarter of 2023, attributed to rising operational costs. However, its financial reserves are projected to sustain operations into 2026.
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data
Xenon Pharmaceuticals (NASDAQ: XENE) announced its financial results for Q2 2023, confirming that patient enrollment for the XEN1101 Phase 2 X-NOVA study in major depressive disorder has completed with a total of 160 patients. Topline results are anticipated by late November to mid-December. The company also reported ongoing progress in its XEN1101 Phase 3 epilepsy trials. Despite the positive advancements, Xenon recorded a net loss of $47.5 million for the quarter, attributed to increased operational costs and no recognized revenue.
Read more →XENEXenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
Xenon Pharmaceuticals has announced the appointment of Dr. Gillian M. Cannon and Mr. Justin Gover to its Board of Directors. Dr. Cannon has over 30 years of experience in the pharmaceutical industry, while Mr. Gover has nearly 25 years, including founding CEO of GW Pharmaceuticals. These appointments are seen as critical as Xenon advances its XEN1101 program in Phase 3 epilepsy trials and prepares for commercialization related to its products. The board believes their expertise will significantly contribute to the company's goals.
Read more →XENEXenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover VANCOUVER, British Columbia
Xenon Pharmaceuticals has announced the appointment of Dr. Gillian M. Cannon and Mr. Justin Gover to its Board of Directors. Dr. Cannon brings over 30 years of experience in the pharmaceutical industry, while Mr. Gover has nearly 25 years of experience, particularly in the epilepsy sector. Their appointments are considered timely as Xenon progresses with its XEN1101 clinical trials. The company is optimistic about the contributions these new leaders will provide as it advances its strategic initiatives in neurology.
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals Inc. will report its second quarter 2023 financial results on August 9, 2023, after U.S. markets close. A conference call and webcast will follow at 4:30 pm Eastern Time to discuss these results and provide a corporate update. This event underscores the company's ongoing commitment to financial transparency and its focus on developing therapies for neurological disorders.
Read more →XENEXenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
Xenon Pharmaceuticals Inc. has announced its participation in the Goldman Sachs 44th Annual Global Healthcare Conference, which will take place on June 12, 2023. The presentation will feature key executives, including President and CEO Ian Mortimer and CFO Sherry Aulin. A live webcast will be available for investors, and the content will be accessible for replay after the event. Xenon is focused on developing therapeutics for neurological disorders, addressing significant unmet medical needs.
Read more →XENEXenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
Xenon Pharmaceuticals Inc. will present at the 2023 Jefferies Healthcare Conference scheduled for June 7-9, 2023, in New York, NY. The company's President and CEO Ian Mortimer and CFO Sherry Aulin will lead the fireside chat, which will also be available for live streaming and replay on their website. This presentation underscores Xenon's commitment to developing therapies for neurological disorders, particularly epilepsy, as part of its ongoing efforts in addressing unmet medical needs.
Read more →XENEXenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 RBC Capital Markets Global Healthcare Conference taking place May 16-17
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials inc
Xenon Pharmaceuticals has reported its financial results for Q1 2023 and provided an update on its ongoing clinical programs. The company is making significant progress with its XEN1101 Phase 3 epilepsy trials, now actively recruiting patients. Additionally, topline data from the Phase 2 X-NOVA trial for major depressive disorder is anticipated by the end of 2023. However, the company also reported a net loss increase and no revenue for the quarter compared to last year, prompting a focus on the financial sustainability of its operations.
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT Phase 3 clinical trials Anticipate last patient to be screened next month in XEN110
Read more →XENEXenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
VANCOUVER, British Columbia, May 03, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2023 taking place May 9-11, 2023. Co
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets o
Read more →XENEXenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
Oral presentation by Dr. Jacqueline French to outline sustained monthly reduction in focal onset seizures during open-label extension of X-TOLE study Poster to present the trial design for Phase 3 X-ACKT clinical study evaluating XEN1101 in additional epilepsy indication of prim
Read more →XENEXenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
BURNABY, British Columbia, April 21, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference to be held
Read more →XENEXenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
BURNABY, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 22nd Annual Needham Virtual Healthcare Conference taking place April 17-20,
Read more →XENEXenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
BURNABY, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual Stifel 2023 CNS Days taking place March 28-29, 2023. Company Firesi
Read more →XENEXenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder expected in third quarter Conference call at 4:30 pm ET today BURNAB
Read more →XENEXenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary gener
Xenon Pharmaceuticals reported its financial results for Q4 2022 and provided updates on its clinical programs, notably the ongoing advancement of its XEN1101 Phase 3 trials for epilepsy and major depressive disorder. With a focus on improving treatments for these conditions, the company anticipates significant data readouts in the coming months. Additionally, despite having $720.8 million in cash, Xenon reported a net loss of $125.4 million for the year, attributing some financial strain to increased research and development costs.
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2022 financial and operating results after the close of U.S. finan
Read more →XENEXenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
BURNABY, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual SVB Securities Global Biopharma Conference taking place from February
Read more →XENEXenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong financial position expected to fully support XEN1101 Phase 3 program development and cash runway into 2026 BURNABY, British Columbia, Jan.
Read more →XENEXenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
BURNABY, British Columbia, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco,
Read more →XENE▲ +5.3%on this news
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
Company Presents Additional Positive Data from Open Label Extension of Phase 2b ‘X-TOLE’ Clinical Trial for Focal Onset Seizures XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking Place on Sunday, December 4, 2022 BURNABY, British Columbia, Dec. 02, 2022 (GLOB
Read more →XENEXenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of A
Read more →XENE▼ -6.6%on this news
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
XEN1101 Phase 3 program launched with initiation of X-TOLE2 clinical trial Strong financial position of approximately $752 million to fully support XEN1101 Phase 3 program development and expected cash runway into 2026 Conference call at 4:30 pm ET today BURNABY, British Colum
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update XEN1101 Phase 3 program launched with initiation of X-TOLE2 clinical trial Strong financial position of approx
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update XEN1101 Phase 3 program launched with initiation of X-TOLE2 clinical trial Strong financial position of approximately $752 million to fully support XEN1101 Phase 3 program developme
Read more →XENEXenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary BURNABY, British Columbia
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary BURNABY, British Columbia, November 7, 2022 Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announc
Read more →XENEXenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. Ms. DiFab
Read more →XENEXenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
BURNABY, British Columbia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the launch of its XEN1101 Phase 3 program with the initiation of the X-TOLE2 clinical trial, which will examine XE
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on
Read more →XENEXenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Ann
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year Cash runway ex
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year Cash runway extended into 2026 following successful completion of equity offering in
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year Cash runway extended into 2026 following successful completion of equity offering in June Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE
Read more →XENEXenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
BURNABY, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in virtual one-on-one investor meetings and a fireside chat presentation at the 1
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets o
Read more →XENEXenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022
BURNABY, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in a fireside chat presentation and one-on-one investor meetings at the William B
Read more →XENEXenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229
Read more →XENE▼ -8.6%on this newsshared move
Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering
BURNABY, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,868,854 common shares and, in lieu of common shares to certain i
Read more →XENE▲ +5.2%on this newsshared move
Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program
New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction New XEN1101 OLE data demonstrates continued seizure reduction exceeding 70% at 3 months in
Read more →XENE▲ +8.2%on this newsshared move
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Dr
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase
Read more →XENE▲ +8.2%on this newsshared move
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical trial (X-TOLE2) along with the completed Phase 2b (X-TOLE) clinical trial Pla
Read more →XENEXenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conf
Read more →XENE▲ +12.3%on this news
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update XEN1101 "End of Phase 2" Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult F
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update XEN1101 "End of Phase 2" Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022 Company-sponsored Pha
Read more →XENE▲ +12.3%on this news
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
XEN1101 “End of Phase 2” Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022 Company-sponsored Phase 2 Clinical Trial Initiated to Evaluate XEN1101 for the Treatment of MDD Conference Call at 4:3
Read more →XENEXenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)
BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the initiation of a Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical study – called the “
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on
Read more →XENE▲ +5.5%on this news
Xenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
BURNABY, British Columbia, April 04, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (
Read more →XENEXenon Pharmaceuticals to Present at Stifel 2022 CNS Days
BURNABY, British Columbia, March 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat at the Stifel 2022 CNS Days
Read more →XENECraig Colosso Relationship Management American Stock Transfer & Trust Company, LLC Brooklyn, NY Office: 718.921.8337 E-mail: ccolosso@astfinancial.com
Craig Colosso Relationship Management American Stock Transfer & Trust Company, LLC Brooklyn, NY Office: 718.921.8337 E-mail: ccolosso@astfinancial.com Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals
Read more →XENEXenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
BURNABY, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the year ended December 31, 2021 and provided a corporate update. Mr. Ian Mortimer, Xenon’s
Read more →XENEXenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update Conference Call at 4:30 pm ET Today BURNABY, British Columbia
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 1, 2022 - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial re
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial results for the year ended December 31, 2021 and provide a corporate update after the
Read more →XENEXenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a virtual fireside chat at the 11th Annual SVB Leerink Globa
Read more →XENEXenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone BURNABY, British Columbia
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone BURNABY, British Columbia, January 12, 2022 - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its
Read more →XENEXenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieve
Read more →XENE▼ -5.9%on this newsshared move
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022
BURNABY, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “We are enter
Read more →XENEXenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)
BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy
Read more →XENEXenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)
Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups Results from New Sub-Analyses Consistent with Positive Topline Data and Demonstrate Strong Efficacy
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022 Confe
Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, November 10,
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on
Read more →XENEXenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,52
Read more →XENE▲ +6.8%on this newsshared move
Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering
BURNABY, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,474,577 common shares and, in lieu of common shares to certain i
Read more →XENE▲ +101.9%on this newsshared move
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy All Primary and Secondary Seizure Reduction Endpoints Statisticall
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg a
Read more →XENE▲ +101.9%on this newsshared move
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups Xenon to Host Conference Call and Live Webcast Today at 7:30 am Eastern Time BURNABY, British Columbia, Oct. 04, 2021 (
Read more →XENE▲ +101.9%on this newsshared move
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101
BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b
Read more →XENEXenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
BURNABY, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achiev
Read more →XENEXenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures i
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults BURNABY, British Columbia, September 8, 2021 - Xenon Pharmaceu
Read more →XENEXenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer
BURNABY, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Kenney, M.D. as Chief Medical Officer, effective immediately. Dr. Kenney will overs
Read more →XENEXenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer BURNABY, British Columbia
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer BURNABY, British Columbia, August 23, 2021 - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appoint
Read more →XENE▲ +11.2%on this news
Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Topline Data from XEN1101 Phase 2b “X-TOLE” Clinical Trial Anticipated Late September to Mid-October 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceut
Read more →XENE▲ +11.2%on this news
Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update Topline Data from XEN1101 Phase 2b "X-TOLE" Clinical Trial Anticipated Late September to Mid-October 2021 Con
Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update Topline Data from XEN1101 Phase 2b "X-TOLE" Clinical Trial Anticipated Late September to Mid-October 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, August 11,
Read more →XENEXenon Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
BURNABY, British Columbia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings as well as a virtual panel discussion at the 12th Annual Wedbush
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets o
Read more →XENEXenon Pharmaceuticals to Participate at the William Blair Biotech Focus Conference 2021
BURNABY, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in a virtual fireside chat at the William Blair Biotech Focus Conference 2021. Date: Thursday,
Read more →XENEXenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders
BURNABY, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today provided an update on its ongoing XEN1101 Phase 2b “X-TOLE” clinical trial, announcing that randomization of 326 patients wa
Read more →XENEXenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders
BURNABY, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders (the “Annual Meeting”) held today on June 3, 2021.
Read more →XENEXenon Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
BURNABY, British Columbia, May 31, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will participate in the following investor conference: Jefferies 2021 V
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Topline Data from XEN1101 Phase 2b "X-TOLE" Clinical Trial Anticipated by End of Third Quarter of 2021 Confere
Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Topline Data from XEN1101 Phase 2b "X-TOLE" Clinical Trial Anticipated by End of Third Quarter of 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 11, 2021 -
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
Topline Data from XEN1101 Phase 2b “X-TOLE” Clinical Trial Anticipated by End of Third Quarter of 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced it will report its first quarter 2021 financial and operating results after the close of U.S. financial markets on Tue
Read more →XENEXenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS Day
BURNABY, British Columbia, March 29, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the Company will participate in a fireside chat at the following virtual investor conference: Stifel 3rd Annua
Read more →XENEXenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
BURNABY, British Columbia, March 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 5,135,135 common shares, which includes 810,
Read more →XENEXenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
BURNABY, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 4,324,325 common shares and, in lieu of common shares to a certai
Read more →XENEXenon Pharmaceuticals Announces Proposed Public Offering of Common Shares
BURNABY, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain
Read more →XENEXenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)
BURNABY, British Columbia, March 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced a collaboration with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to facilitate an investigator-sponsor
Read more →XENEXenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update XEN1101 Phase 2b "X-TOLE" Clinical Trial in Adult Focal Epilepsy on Track for Topline Data in Third Quarter of 2021 Conferen
Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update XEN1101 Phase 2b "X-TOLE" Clinical Trial in Adult Focal Epilepsy on Track for Topline Data in Third Quarter of 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 1, 2021
Read more →XENEXenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update
XEN1101 Phase 2b “X-TOLE” Clinical Trial in Adult Focal Epilepsy on Track for Topline Data in Third Quarter of 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused bi
Read more →XENEXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2020 Financial Results
BURNABY, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced it will report its 2020 financial and operating results after the close of U.S. financial markets on Monday, March 1,
Read more →XENEXenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021
Pre-Clinical Data Support the Potential Benefit of XEN1101 to Treat Depression and Anhedonia XEN1101, in Combination with Other Anti-Seizure Medications, Provides Robust Efficacy in Animal Models Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy o
Read more →XENEXenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021 Simon Pimstone to Assume New Role as Executive Chair and Ian Mortimer to be Named Chief Executive Officer
Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021 Simon Pimstone to Assume New Role as Executive Chair and Ian Mortimer to be Named Chief Executive Officer at Annual Meeting of Shareholders in June 2021 Topline Data from XEN110
Read more →XENEXenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021
Simon Pimstone to Assume New Role as Executive Chair and Ian Mortimer to be Named Chief Executive Officer at Annual Meeting of Shareholders in June 2021 Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021 Phase 3 X
Read more →XENEXenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy Society
BURNABY, British Columbia, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced updates on its proprietary and partnered neurology programs at AES2020, the virtual Annual Meeting of the American Epile
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Experienced Biotech Executive, Patrick Machado, Joins Xenon's Board of Directors Conference Call at 4:30 pm ET
Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Experienced Biotech Executive, Patrick Machado, Joins Xenon's Board of Directors Conference Call at 4:30 pm ET Today BURNABY, British Columbia, November 5, 2020 - Xenon Pharmaceuti
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Experienced Biotech Executive, Patrick Machado, Joins Xenon’s Board of Directors Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today repor
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its third quarter 2020 financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-End
BURNABY, British Columbia, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today provided regulatory updates on its proprietary pediatric neurology program, XEN496, a Kv7 potassium channel modulator that i
Read more →XENEXenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer BURNABY, British Columbia
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer BURNABY, British Columbia, August 17, 2020 - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced today the appointment of Dr. Chris Von Seggern as Chie
Read more →XENEXenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer
BURNABY, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced today the appointment of Dr. Chris Von Seggern as Chief Commercial Officer, effective immediately. In this newly created
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020 Conference Call at 4:30 pm
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, August 6, 2020 - Xenon Pharmaceuti
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today repo
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update
BURNABY, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its second quarter 2020 financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
BURNABY, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present a company overview at the Jefferies Virtual He
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs Additional FDA Feedback Suppor
Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs Additional FDA Feedback Supports Commencement of XEN496 Phase 3 Clinical Trial in 2020 Conference Ca
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs Additional FDA Feedback Supports Commencement of XEN496 Phase 3 Clinical Trial in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 21, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmace
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2020 financial and operating results after the close of U.S. financial markets o
Read more →XENEXenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19
BURNABY, British Columbia, March 31, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update in the context of the developing situation with the COVID-19 pandemic. Dr. Simon Pimstone, Xenon’
Read more →XENEXenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update Xenon's Robust Neurology Pipeline of Proprietary and Partnered Programs Advances with Multiple Important Milestone Opportuni
Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update Xenon's Robust Neurology Pipeline of Proprietary and Partnered Programs Advances with Multiple Important Milestone Opportunities Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY,
Read more →XENEXenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update
Xenon’s Robust Neurology Pipeline of Proprietary and Partnered Programs Advances with Multiple Important Milestone Opportunities Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 09, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nas
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update
BURNABY, British Columbia, March 02, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2019 financial and operating results after the close of U.S. financial markets on Monday, Ma
Read more →XENEXenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
BURNABY, British Columbia, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced public offering of 3,750,000 common shares, which initially closed
Read more →XENEXenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares
BURNABY, British Columbia, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced public offering of 3,750,000 common shares pursuant to its existing shelf reg
Read more →XENEXenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares
BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,750,000 common shares pursuant to its existing shelf registratio
Read more →XENEXenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
Xenon’s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered Programs Experienced Biotech Executive, Dr. Clarissa Desjardins, Joins
Read more →XENEXenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the “Genetic Epilepsies – Updates in the Science and Diagnosis” Exhibit in Room 318-319 on Sunday, December 8th Pre-Clinical Work Suggests Selective Sodium Channel Inhibitors that Reduce Action Poten
Read more →XENEXenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
Xenon’s Epilepsy Programs Continue to Advance Including Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy and Plans for Anticipated Pediatric XEN496 Pivotal Phase 3 Clinical Trial in KCNQ2-DEE Patients Promising New Pre-Clinical Data Support Precision Medicine Appr
Read more →XENEXenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference
BURNABY, British Columbia, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Co
Read more →XENENeurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibi
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon R
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences
BURNABY, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at 8:30 am Eastern Time (5:30 am Pacific Time) today to provide
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update In Addition to Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy, Company Advances Epilepsy Prog
Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update In Addition to Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy, Company Advances Epilepsy Programs and Anticipates Initiating Pediatric Clinical Trials in KCNQ2 (XE
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
In Addition to Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy, Company Advances Epilepsy Programs and Anticipates Initiating Pediatric Clinical Trials in KCNQ2 (XEN496) and SCN8A (XEN901) Developmental and Epileptic Encephalopathies in 2020 XEN007 Phase 2 Proo
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2019 financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
BURNABY, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the 2019 Cantor Global
Read more →XENEXenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human Resources
BURNABY, British Columbia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, announced that Shelley McCloskey has joined the company’s leadership team as Senior Vice President, Human Resources. Ms. McCloskey
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update Anticipate Testing of New Pediatric Formulations of XEN496 and XEN901 in Adults in Third Quarter, Followed by
Xenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update Anticipate Testing of New Pediatric Formulations of XEN496 and XEN901 in Adults in Third Quarter, Followed by IND Submissions to Initiate Pediatric Clinical Trials in KCNQ2 and SC
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Anticipate Testing of New Pediatric Formulations of XEN496 and XEN901 in Adults in Third Quarter, Followed by IND Submissions to Initiate Pediatric Clinical Trials in KCNQ2 and SCN8A Developmental and Epileptic Encephalopathies Conference Call at 4:30 pm ET Today BURNABY, Bri
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update
BURNABY, British Columbia, July 31, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2019 financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals Presents Corporate Update on Neurology-Focused Pipeline at the Jefferies 2019 Healthcare Conference
Company Highlights Recent Regulatory Feedback Guiding the Clinical Development of XEN901 into Pediatric SCN8A-EE Patients Webcast of Conference Presentation at 11:00 am ET Today BURNABY, British Columbia, June 05, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE
Read more →XENEXenon Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
BURNABY, British Columbia, May 29, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Jefferies 2019 Health
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in Phase 2 or Lat
Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in Phase 2 or Later Stage Development this Year Conference Call at 4:30 pm ET Today BU
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in Phase 2 or Later Stage Development this Year Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 07, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE),
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update
BURNABY, British Columbia, April 30, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2019 financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
BURNABY, British Columbia, April 24, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Bloom Burton & Co.
Read more →XENECraig Colosso Relationship Manager American Stock Transfer & Trust Company, LLC Charlotte, North Carolina Tel: 718.921.8337 Email: ccolosso@amstock.com www.amstock.com
Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual
Read more →XENEXenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b
Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial Underway with Data Anticipated in Second Half of 2020 C
Read more →XENEXenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update
Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial Underway with Data Anticipated in Second Half of 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 06, 2019 (GLOBE
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2018 financial and operating results after the close of U.S. financial markets on Wednesday,
Read more →XENEXenon Provides Key Regulatory Updates on XEN007 and XEN1101
FDA Grants Rare Pediatric Disease Designation to XEN007 for Alternating Hemiplegia of Childhood (AHC); Xenon Eligible to Apply for Priority Review Voucher IND for XEN1101 Accepted; Site Selection and Patient Enrollment Underway in Canada and the United States for XEN1101 Phase 2
Read more →XENEXenon Pharmaceuticals Outlines 2019 Key Milestones
BURNABY, British Columbia, Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key milestone events in 2019. Dr. Simon Pimstone, Xenon’s Chief Execu
Read more →XENEXenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting
XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 Clinical Trial in Adult Focal Epilepsy; U.S. IND Filing Targeted in Q1 2019 Conference Call to Discuss Xenon’s Epilepsy Programs at 9 am ET Today BURNABY, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Xenon
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting
BURNABY, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 am Eastern Time (6:00
Read more →XENEXenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
BURNABY, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Stifel 2018 Healthca
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Robust, Novel Pipeline of Neurology Candidates Advancing in Clinical Development Conference Call at 4:30 pm ET
Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Robust, Novel Pipeline of Neurology Candidates Advancing in Clinical Development Conference Call at 4:30 pm ET Today BURNABY, British Columbia, November 6, 2018 -- Xenon Pharmaceut
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Robust, Novel Pipeline of Neurology Candidates Advancing in Clinical Development Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2018 financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common Shares
BURNABY, British Columbia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the closing of its previously announced public offering of 4,500,000 common shares pursuant to it
Read more →XENEXenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares
BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 4,500,000 common shares pursuant to its existi
Read more →XENEXenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program
BURNABY, British Columbia, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced it has signed an agreement with Valeant Pharmaceuticals Luxembourg S.a.r.l. and Valeant Pharmaceu
Read more →XENEXenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program BURNABY, British Columbia
Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program BURNABY, British Columbia, September 10, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced it has signed
Read more →XENEXenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a "Phase 3 Ready" Potassium Channel Modulator for the Treatment of Epilepsy Single, Pivotal Phase 3 Clinical Trial in Approximately 20 KC
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a "Phase 3 Ready" Potassium Channel Modulator for the Treatment of Epilepsy Single, Pivotal Phase 3 Clinical Trial in Approximately 20 KCNQ2-EE Patients Expected to be Initiated in Mid-2019 Conference Call T
Read more →XENEXenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy
Single, Pivotal Phase 3 Clinical Trial in Approximately 20 KCNQ2-EE Patients Expected to be Initiated in Mid-2019 Conference Call Today at 8:00 am ET Xenon to Webcast Update on Epilepsy Pipeline from Biocentury NewsMakers Conference on September 7, 2018 BURNABY, British Columb
Read more →XENEXenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study XEN1101 Demonstrates Statistically Significant Reduction in Corticospinal and Cortical Excitability as Measured by TMS-EMG and TM
Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study XEN1101 Demonstrates Statistically Significant Reduction in Corticospinal and Cortical Excitability as Measured by TMS-EMG and TMS-EEG XEN1101 Demonstrates Greater Effect on TMS-EMG Resting Motor Thre
Read more →XENEXenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study
XEN1101 Demonstrates Statistically Significant Reduction in Corticospinal and Cortical Excitability as Measured by TMS-EMG and TMS-EEG XEN1101 Demonstrates Greater Effect on TMS-EMG Resting Motor Threshold at Significantly Lower Dose When Compared to Historical Ezogabine Data X
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update Novel Epilepsy Product Candidates - XEN1101 and XEN901 - Continue to Advance in the Clinic New XEN1101 Phase
Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update Novel Epilepsy Product Candidates - XEN1101 and XEN901 - Continue to Advance in the Clinic New XEN1101 Phase 1b TMS Pharmacodynamic Data to be Presented at upcoming European Congre
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Novel Epilepsy Product Candidates – XEN1101 and XEN901 – Continue to Advance in the Clinic New XEN1101 Phase 1b TMS Pharmacodynamic Data to be Presented at upcoming European Congress on Epileptology BURNABY, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceutic
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2018 financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals Announces At-The-Market Equity Offering
BURNABY, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, announced today that it has entered into an at-the-market equity offering sales agreement with Jefferies and Stifel, effective as of
Read more →XENEXenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
BURNABY, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Jefferies 2018 Healt
Read more →XENEXenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference Company to Hold Conference Call at 8:00 am ET Today Preliminary Phase 1 Clinical Data Support Drug Expo
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference Company to Hold Conference Call at 8:00 am ET Today Preliminary Phase 1 Clinical Data Support Drug Exposure Levels Higher than Required in Pre-clinical Efficacy Models with E
Read more →XENEXenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference
Company to Hold Conference Call at 8:00 am ET Today Preliminary Phase 1 Clinical Data Support Drug Exposure Levels Higher than Required in Pre-clinical Efficacy Models with Excellent Tolerability and Safety New Pre-clinical Data Support Selective Nav1.6 Mechanism of Action and
Read more →XENEXenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference
Company to Hold Conference Call at 8:00 am ET Today XEN1101 Pilot TMS-EEG Data Demonstrates Statistically Significant Effect of 20mg Dose versus Baseline (p<0.01) and Greater Effect on TMS-EMG Resting Motor Threshold at Significantly Lower Dose When Compared to Ezogabine Phase
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of XEN1101 and XEN901 Presentations at 14th Eilat Conference
BURNABY, British Columbia, May 14, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will provide a corporate update and overview of the presentations on its proprietary epilepsy products, XEN110
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update Xenon's novel clinical stage epilepsy candidates, XEN1101 and XEN901, to be presented at upcoming 14th Eilat C
Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update Xenon's novel clinical stage epilepsy candidates, XEN1101 and XEN901, to be presented at upcoming 14th Eilat Conference on New Antiepileptic Drugs and Devices on May 15, 2018 BURNA
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Xenon’s novel clinical stage epilepsy candidates, XEN1101 and XEN901, to be presented at upcoming 14th Eilat Conference on New Antiepileptic Drugs and Devices on May 15, 2018 BURNABY, British Columbia, May 08, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 01, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets o
Read more →XENEXenon Pharmaceuticals to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
BURNABY, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Bloom Burton & Co.
Read more →XENEXenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P. BURNABY, British Columbia
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P. BURNABY, British Columbia, March 28, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today report
Read more →XENEXenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.
BURNABY, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported the closing of the previously announced transaction with Teva Pharmaceuticals International GmbH, along with Teva Can
Read more →XENEDr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer Changes to Senior Leadership Support Expanding Neurology Pipeline BURNABY, British Columbia
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer Changes to Senior Leadership Support Expanding Neurology Pipeline BURNABY, British Columbia, March 13, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today an
Read more →XENEXenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update Two novel anti-epileptic drugs advancing in clinical development; Interim XEN1101 Phase 1 data expected to be released in Ma
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update Two novel anti-epileptic drugs advancing in clinical development; Interim XEN1101 Phase 1 data expected to be released in May 2018 at scientific symposium; Xenon announces new clinical stage ion
Read more →XENEXenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update
Two novel anti-epileptic drugs advancing in clinical development; Interim XEN1101 Phase 1 data expected to be released in May 2018 at scientific symposium; Xenon announces new clinical stage ion channel product to expand its neurology pipeline BURNABY, British Columbia, March
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 financial and operating results after the close of U.S. financial markets on Wednesday,
Read more →XENEXenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial
BURNABY, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of its proprietary epilepsy product candidate, XEN901, which is an orally
Read more →XENEXenon Pharmaceuticals Outlines Key Milestones for 2018 BURNABY, British Columbia
Xenon Pharmaceuticals Outlines Key Milestones for 2018 BURNABY, British Columbia, January 8, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key corporate milestones for
Read more →XENEXenon Pharmaceuticals Outlines Key Milestones for 2018
BURNABY, British Columbia, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key corporate milestones for 2018. Dr. Simon Pimstone, Xenon's Presid
Read more →XENEXenon Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
BURNABY, British Columbia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Stifel
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
BURNABY, British Columbia, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2017, and provided a corporate update. Dr. Simon Pimstone,
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update BURNABY, British Columbia
Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update BURNABY, British Columbia, November 7, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quar
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 third quarter financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial
Xenon’s innovative, proprietary epilepsy programs continue to advance in development Pharmacodynamic read-out expected in Q1 2018 and XEN1101 Phase 2 proof-of-concept clinical trial anticipated to begin in Q3 2018 BURNABY, British Columbia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Xe
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update BURNABY, British Columbia
Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update BURNABY, British Columbia, August 3, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quart
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
BURNABY, British Columbia, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended June 30, 2017, and provided a corporate update for 2017. Dr. Simon Pimsto
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, July 27, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 second quarter financial and operating results after the close of U.S. financial markets
Read more →XENETeva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint Jerusalem & Burnaby, British Columbia
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint Jerusalem & Burnaby, British Columbia -- June 27, 2017 -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Xenon Pharmaceuticals I
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN
BURNABY, British Columbia, June 27, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) today to disc
Read more →XENEXenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
BURNABY, British Columbia, June 02, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Jeffer
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update BURNABY, British Columbia, May 9 , 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharm
Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update BURNABY, British Columbia, May 9, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company today, reported its financial results for the quarter e
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
BURNABY, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company today, reported its financial results for the quarter ended March 31, 2017, and provided a corporate update for 2017. Dr. Simon Pimsto
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 04, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 first quarter financial and operating results after the close of U.S. financial markets o
Read more →XENEXenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
BURNABY, British Columbia, April 28, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Bloom
Read more →XENEXenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
Phase 1 expected to begin in Q4 2017, with pharmacodynamic read-out in Q1 2018 and Phase 2 proof-of-concept clinical trial beginning in mid-2018 Conference call to be held today at 9:00 am ET BURNABY, British Columbia, April 26, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals In
Read more →XENEXenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy Phase 1 expected to begin in Q4 2017, with pharmacodynamic read-out in Q1 2018 a
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy Phase 1 expected to begin in Q4 2017, with pharmacodynamic read-out in Q1 2018 and Phase 2 proof-of-concept clinical trial beginning in mid-2018 Conf
Read more →XENEXenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne Company to Hold Conference Call at 8:30 am ET Today BURNABY, British
Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne Company to Hold Conference Call at 8:30 am ET Today BURNABY, British Columbia, March 24, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE),
Read more →XENEXenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne
BURNABY, British Columbia, March 24, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, parallel-group study designed to ev
Read more →XENEDeana Fuhriman Senior Relationship Manager American Stock Transfer & Trust Company, LLC Seattle, Washington Tel: 718.921.8553 Email: dfuhriman@amstock.com www.amstock.com
Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual
Read more →XENEXenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update BURNABY, British Columbia
Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update BURNABY, British Columbia, March 8, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the year ended December 3
Read more →XENEXenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, March 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2016, and provided a corporate update for 2017. Dr. Simon Pims
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, March 01, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 financial and operating results after the close of U.S. financial markets on Wednesday,
Read more →XENEXenon Pharmaceuticals Outlines Key Milestones for 2017
BURNABY, British Columbia, Jan. 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2017. Dr. Simon Pimstone, Xenon's President and Chief Executive Officer,
Read more →XENEXenon Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference
BURNABY, British Columbia, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Stifel
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2016 and provided a corporate update. Dr. Simon Pimstone, X
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update BURNABY, British Columbia
Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update BURNABY, British Columbia, November 3, 2016 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quar
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 third quarter financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors BURNABY, British Columbia
Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors BURNABY, British Columbia, September 27, 2016 - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dawn Svoronos has been appointed to its Board of Dire
Read more →XENEXenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
BURNABY, British Columbia, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dawn Svoronos has been appointed to its Board of Directors. Ms. Svoronos is a pharmaceutical industry executive
Read more →XENEXenon Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Closing of $34.5 Million Public Offering
BURNABY, British Columbia, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that the underwriters of the previously announced public offering of its common shares have exercised in full their
Read more →XENEXenon Pharmaceuticals Announces Pricing of $30 Million Public Offering of Common Shares
BURNABY, British Columbia, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the pricing of a $30 million underwritten public offering of its common shares pursuant to its existing shelf regist
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update BURNABY, British Columbia
Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update BURNABY, British Columbia, August 3, 2016 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quart
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended June 30, 2016 and provided a corporate update. Dr. Simon Pimstone, Xenon'
Read more →XENEXenon Pharmaceuticals to Present at the Canaccord Genuity 36th Annual Growth Conference
BURNABY, British Columbia, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Canacc
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, July 25, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 second quarter financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic Programs at the Jefferies 2016 Healthcare Conference
BURNABY, British Columbia, June 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present today at the Jefferies 2016 Healthcare
Read more →XENEXenon Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
BURNABY, British Columbia, June 02, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Jeffer
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update BURNABY, British Columbia
Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update BURNABY, British Columbia, May 10, 2016 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, May 10, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended March 31, 2016 and provided a corporate update. Dr. Simon Pimstone, Xenon'
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 02, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 first quarter financial and operating results after the close of U.S. financial markets o
Read more →XENEXenon Names Dr. Raymond J. Winquist as Head, Translational Research
BURNABY, British Columbia, April 04, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Raymond J. Winquist has been named as its Head, Translational Research, effective immediately. Reporting to
Read more →XENEXenon Pharmaceuticals to Provide Business and Milestone Update at Needham Healthcare Conference
BURNABY, British Columbia, March 31, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a business update, including pr
Read more →XENEXenon and Genentech Extend Collaborations Focused on Pain
BURNABY, British Columbia, March 15, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today provided an update on its two ongoing collaborations focused on identifying and developing novel pain targets and therapeutics
Read more →XENEJoshua P. McGinn, CEP Senior Vice President, Western Region Relationship Management American Stock Transfer & Trust Company, LLC One Embarcadero Center - Suite 566 San Francisco, CA 94111 Office: 415.835-1313
Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual
Read more →XENEXenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update
Significant Progress in Proprietary Development Pipeline and Partnered Programs Initiated Phase 2 Trial of XEN801 in Moderate to Severe Acne; Results Anticipated in Fourth Quarter of 2016 BURNABY, British Columbia, March 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (
Read more →XENEXenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update Significant Progress in Proprietary Development Pipeline and Partnered Programs Initiated Phase 2 Tria
Xenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update Significant Progress in Proprietary Development Pipeline and Partnered Programs Initiated Phase 2 Trial of XEN801 in Moderate to Severe Acne; Results Anticipated in Fourth Quarter of 2016 BURNAB
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2015 Financial Results and Provide Corporate Update
BURNABY, British Columbia, March 01, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 financial and operating results after the close of U.S. financial markets on Tuesday, M
Read more →XENEXenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne
BURNABY, British Columbia, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing patients in a Phase 2 clinical trial of XEN801, which is a stearoyl Co-A desaturase-1, o
Read more →XENEXenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery
BURNABY, British Columbia, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. James R. Empfield has been named as Senior Vice President, Drug Discovery, effective immediately. Reporting
Read more →XENEXenon Outlines Key Milestones for 2016
BURNABY, British Columbia, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2016. Dr. Simon Pimstone, Xenon’s President and Chief Executive Officer,
Read more →XENEXenon and Genentech Publish in Science the 3-D Crystal Structure of a Novel Nav1.7 Compound Binding Site Enabling the Development of Potent Selective Inhibitors to Treat Pain
BURNABY, British Columbia, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced publication of a key article in Science by researchers at Xenon and Genentech describing for the first time the X-ray
Read more →XENEXenon Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference
BURNABY, British Columbia, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Stifel
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update
Progress Includes Initiation of XEN801 Phase 1 Clinical Trial and Achievement of Milestones in Genentech Nav1.7 Clinical Program and Pain Genetics Collaboration Conference Call/Webcast Today at 5:00 p.m. Eastern Time BURNABY, British Columbia, Nov. 10, 2015 (GLOBE NEWSWIRE) --
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2015 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 third quarter financial and operating results after the close of U.S. financial markets o
Read more →XENEXenon Announces Its Partner Genentech Has Advanced GDC-0310, a Second Nav1.7 Inhibitor for Pain, Into Clinical Development
BURNABY, British Columbia, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that the Company's partner Genentech, a member of the Roche Group, has advanced a second Nav1.7 inhibitor into clinic
Read more →XENEXenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial
BURNABY, British Columbia, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of its lead proprietary program, XEN801, as a potential treatment for acn
Read more →XENEXenon Pharmaceuticals Achieves Milestone in Genentech Collaboration to Discover Novel Pain Targets
BURNABY, British Columbia, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that the Company has achieved a milestone in its pain genetics discovery collaboration with Genentech, a member of t
Read more →XENEXenon Pharmaceuticals to Present at the 10th Annual Wells Fargo Healthcare Conference
BURNABY, British Columbia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the 10th A
Read more →XENEXenon Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Continued Pipeline Progress in Partnered and Proprietary Programs; Conference Call/Webcast Today at 4:30 p.m. Eastern Time BURNABY, British Columbia, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical-stage biopharmaceutical company, today r
Read more →XENEXenon Pharmaceuticals to Present at the Canaccord Genuity 35th Annual Growth Conference
BURNABY, British Columbia, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Canacco
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2015 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 second quarter financial and operating results after the close of U.S. financial markets
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss TV-45070 Phase 2b Study in Osteoarthritis Pain
BURNABY, British Columbia, July 1, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) today to discu
Read more →XENEXenon Pharmaceuticals to Provide Business and Milestone Update at Jefferies 2015 Global Healthcare Conference
BURNABY, British Columbia, May 28, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a business update, including prog
Read more →XENEXenon Pharmaceuticals Appoints Steven Gannon to Its Board of Directors
BURNABY, British Columbia, May 22, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Steven Gannon has been appointed to its Board of Directors, where he will also serve on the Company's Audit Commi
Read more →XENEXenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
Continued Pipeline Progress in Partnered and Proprietary Programs Conference Call/Webcast Today at 4:30 p.m. Eastern Time BURNABY, British Columbia, May 12, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today repo
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2015 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 7, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 first quarter financial and operating results after the close of U.S. financial markets on
Read more →XENEXenon Pharmaceuticals Appoints Dr. Richard H. Scheller to Its Board of Directors
BURNABY, British Columbia, March 16, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Richard H. Scheller, Ph.D., has been appointed to its Board of Directors. Dr. Scheller is a globally recognized
Read more →XENEXenon Pharmaceuticals Reports 2014 Financial Results and Provides Corporate Update
Progress in Partnered Programs and Proprietary Development Pipeline Conference Call/Webcast Today at 4:30 p.m. Eastern Time BURNABY, British Columbia, March 12, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today
Read more →XENEXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2014 Financial Results and Provide Corporate Update
BURNABY, British Columbia, March 9, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2014 financial and operating results after the close of U.S. financial markets on Thursday, M
Read more →XENEXenon Pharmaceuticals' Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia
BURNABY, British Columbia, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that its development and commercialization partner Teva Pharmaceutical Industries Ltd. will initiate a Phase 2b clini
Read more →XENEXenon Pharmaceuticals Outlines Key Anticipated Milestones for 2015
BURNABY, British Columbia, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated 2015 milestones, combining near-term expected advances in the company's partnered clinical-stage progra
Read more →XENEXenon Pharmaceuticals Reports Third Quarter 2014 Financial Results
BURNABY, British Columbia, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the third quarter ended September 30, 2014 and provided a corporate update. Dr. Simon Pimst
Read more →XENEXenon Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BURNABY, British Columbia, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced initial public offering of 4,600,000 of its common shares at a price to the p
Read more →XENEXenon Pharmaceuticals Announces Pricing of Initial Public Offering
BURNABY, British Columbia, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 4,000,000 of its common shares at a price to the public of $9.00 per sha
Read more →Competitive Position
How XENE ranks across every disease it competes inCompetitive Position is a premium feature
See how XENE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial